- Home
- DARE vs NRXP Comparison
DARE vs NRXP Comparison
Compare DARE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- NRXP
- Stock Information
- Founded
- DARE 2015
- NRXP 2015
- Country
- DARE United States
- NRXP United States
- Employees
- DARE N/A
- NRXP N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- DARE Health Care
- NRXP Health Care
- Exchange
- DARE Nasdaq
- NRXP Nasdaq
- Market Cap
- DARE 26.3M
- NRXP 32.6M
- IPO Year
- DARE N/A
- NRXP N/A
- Fundamental
- Price
- DARE $2.64
- NRXP $3.01
- Analyst Decision
- DARE Strong Buy
- NRXP Strong Buy
- Analyst Count
- DARE 3
- NRXP 4
- Target Price
- DARE $12.50
- NRXP $28.50
- AVG Volume (30 Days)
- DARE 4.3M
- NRXP 190.3K
- Earning Date
- DARE 08-11-2025
- NRXP 08-13-2025
- Dividend Yield
- DARE N/A
- NRXP N/A
- EPS Growth
- DARE N/A
- NRXP N/A
- EPS
- DARE N/A
- NRXP N/A
- Revenue
- DARE $25,909.00
- NRXP N/A
- Revenue This Year
- DARE $74,787.57
- NRXP N/A
- Revenue Next Year
- DARE $141.76
- NRXP N/A
- P/E Ratio
- DARE N/A
- NRXP N/A
- Revenue Growth
- DARE N/A
- NRXP N/A
- 52 Week Low
- DARE $2.11
- NRXP $1.10
- 52 Week High
- DARE $9.19
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- DARE 49.09
- NRXP 42.90
- Support Level
- DARE $2.11
- NRXP $3.12
- Resistance Level
- DARE $9.19
- NRXP $3.53
- Average True Range (ATR)
- DARE 0.59
- NRXP 0.18
- MACD
- DARE 0.05
- NRXP -0.06
- Stochastic Oscillator
- DARE 7.77
- NRXP 1.89
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.